HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

H Luo; H Quan; C Xie; Y Xu; L Fu; L Lou

首页> 外文期刊>Leukemia >HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

【24h】

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

机译：HH-GV-678是Bcr-Abl的新型选择性抑制剂，其表现优于伊马替尼，并有效地超越了伊马替尼的耐药性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia》 |2010年第10期|共3页
作者
H Luo; H Quan; C Xie; Y Xu; L Fu; L Lou;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. [J] . Gumireddy K, Baker SJ, Cosenza SC, Proceedings of the National Academy of Sciences of the United States of America . 2005,第6期

机译：BATP-ABL的非ATP竞争性抑制剂优于伊马替尼耐药性。
2. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. [J] . Morinaga K, Yamauchi T, Kimura S, International Journal of Cancer =: Journal International du Cancer . 2008,第11期

机译：使用SRC抑制剂CGP76030，ABL抑制剂NILOTINIB和NORMED的K562变体中的ABL / LYN抑制剂INNO-406具有BCR-ABL基因扩增。
3. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. [J] . le-Coutre P, Ottmann OG, Giles F, Blood: The Journal of the American Society of Hematology . 2008,第4期

机译：尼罗替尼（以前的AMN107）是一种高度选择性的BCR-ABL酪氨酸激酶抑制剂，对伊马替尼耐药或不耐受的加速期慢性粒细胞白血病患者有效。
4. Nuclear Entrapment of the BCR-ABL Oncoprotein by the Combination of Imatinib Mesylate and Leptomycin B Kills CML Cells [C] . P. Vigneri, A. Aloisi, S. Di Gregorio, International conference on tumor microenvironment . 2004

机译：通过伊马替尼甲磺酸伊替尼酸甲磺酸盐和百霉素B的组合核截留BCR-ABL癌蛋白杀死CML细胞
5. Addicted to Autophagy: Ph+ B-ALL May Acquire Imatinib-resistance and Enhanced Malignancy through a Highly-active Autophagy Pathway. [D] . Arkus, Nohea. 2011

机译：沉迷于自噬：Ph + B-ALL可通过高度活跃的自噬途径获得伊马替尼抗性和增强的恶性肿瘤。
6. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance [O] . Kiranmai Gumireddy, Stacey J. Baker, Stephen C. Cosenza, 2005

机译：BCR-ABL的非ATP竞争性抑制剂可抑制伊马替尼耐药
7. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance [O] . Gumireddy, Kiranmai, Baker, Stacey J., Cosenza, Stephen C., 2005

机译：BCR-ABL的非ATP竞争性抑制剂可抑制伊马替尼耐药
8. Combinations of Novel Histone Deacetylase and Bcr-Abl Inhibitors in the Therapy of Imatinib Mesylate-Sensitive and -Refractory Bcr-Abl Expressing Leukemia [R] . Bhalla, K. 2008

机译：新型组蛋白去乙酰化酶和Bcr-abl抑制剂联合治疗伊马替尼甲磺酸盐敏感和难治性Bcr-abl表达白血病

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

著录项

相似文献

相关主题

期刊订阅